Abstract: In an embodiment, the present disclosure pertains to a composition having a cation and an anion. In some embodiments, a base is incorporated into the anion, and the cation and the anion form a bifunctional catalyst. In some embodiments, the cation is a chiral cobalt(III) species, and a nitrogenous Brpnsted base is incorporated into counter anions of the chiral cobalt(III) species cation. In some embodiments, the bifunctional catalyst is a tricationic cobalt(III) hydrogen bond donor catalyst, and a nitrogenous Brpnsted base is incorporated into counter anions of the tricationic cobalt(III) hydrogen bond donor catalyst. In another aspect, the present disclosure pertains to a bifunctional catalyst having a smart anion with a cationic metal species. In some embodiments, the smart anion performs a specific role in a chemical reaction without the inclusion of additional external components to accomplish a same specific role in the chemical reaction.

Abstract: In an embodiment, a composition including a chiral solvating agent to resolve nuclear magnetic resonance signals of an enantiomer of at least one analyte, where the chiral solvating agent facilitates in the at least one analyte binding to a C2 face or a C3 face of the chiral solvating agent, and where the chiral solvating agent causes an upfield shift or a downfield shift in at least one nuclear magnetic resonance signals corresponding to a 1H, 19F{1H}, or 31P{1H} signal, and where the chiral solvating agent includes a cobalt cation. In another embodiment, a method that includes mixing a chiral solvating agent, including a cobalt cation, with at least one analyte to form a solution, obtaining nuclear magnetic resonance spectra of the solution, and identifying an enantiomer of the at least one analyte. In some embodiments, the method further includes determining enantiomeric purities of the at least one analyte.

Abstract: In an embodiment, a composition including a chiral solvating agent to resolve nuclear magnetic resonance signals of an enantiomer of at least one analyte, where the chiral solvating agent facilitates in the at least one analyte binding to a C2 face or a C3 face of the chiral solvating agent, and where the chiral solvating agent causes an upfield shift or a downfield shift in at least one nuclear magnetic resonance signals corresponding to a 1H, 19F{1H}, or 31P{1H} signal, and where the chiral solvating agent includes a cobalt cation. In another embodiment, a method that includes mixing a chiral solvating agent, including a cobalt cation, with at least one analyte to form a solution, obtaining nuclear magnetic resonance spectra of the solution, and identifying an enantiomer of the at least one analyte. In some embodiments, the method further includes determining enantiomeric purities of the at least one analyte.

Abstract: In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula ?-[M (x,y)-L1 (w,v)-L2 (t,u)-L3]p+An?mZ?p?m. In an embodiment of the present disclosure ? may be ?. In another embodiment ? may be ?. In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L1, L2, and L3 independently is a ligand comprising a substituted diamine. In some embodiments, An? comprises a lipophilic anion, where m is from 1 to 3, and where Z? comprises an optional second anion.

Abstract: The present invention relates to polymerisation catalysts.

Abstract: In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula ?-[M (x,y)-L1 (w,v)-L2 (t,u)-L3]p+An?mZ?p-m. In an embodiment of the present disclosure ? may be ?. In another embodiment ? may be ?. In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L1, L2, and L3 independently is a ligand comprising a substituted diamine. In some embodiments, An? comprises a lipophilic anion, where m is from 1 to 3, and where Z? comprises an optional second anion.

Abstract: In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula ?-[M(x,y)-L1(w,v)-L2(t,u)-L3]p+An?mZ?p_m. In an embodiment of the present disclosure ? may be A. In another embodiment ? may be ?. In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L1, L2, and L3 independently is a ligand comprising a substituted diamine. In some embodiments, An? comprises a lipophilic anion, where m is from 1 to 3, and where Z? comprises an optional second anion.

Abstract: In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula ?-[M(x,y)-L1(w,v)-L2(t,u)-L3]p+An?mZ?p—m. In an embodiment of the present disclosure ? may be A. In another embodiment ? may be ?. In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L1, L2, and L3 independently is a ligand comprising a substituted diamine. In some embodiments, An? comprises a lipophilic anion, where m is from 1 to 3, and where Z? comprises an optional second anion.

Abstract: The present invention discloses efficient methods for preparing substituted cyclopentadienyl-fluorenyl catalyst components having a mono-carbon bridge.

Abstract: The present invention discloses a chelate ligand wherein the backbone contains a metal.

Abstract: A fluorous delivery or recovery material comprising a fluorous support material having a coating thereon, the coating comprising an amount of a fluorous reaction component that may be dispensed using non-gravimetric methods is disclosed. Also disclosed are methods for dispensing a fluorous reaction component comprising dispensing by non-gravimetric methods a predetermined amount of the fluorous reaction component as a coating on a fluorous support material.

Abstract: Anchorage-dependent cells are grown in a novel cell culture plate and on a novel substratum which increase the oxygenation of the cells. The cell culture plate is made by enclosing a growth chamber within a shell made of a solid sterilizable. One or more culture wells are positioned within the chamber. An inlet port and outlet port are fashioned within the shell for gas exchange. The wells have a well wall which allows for the diffusion of oxygen from the chamber into the well. A perfluorocarbon is placed within the well. A perfluoro-aldehyde is mixed with the perfluorocarbon, and the perfluoro-aldehyde re-orients so that the aldehyde head groups are at the interface. An attachment factor is bound to the perfluoro-aldehyde, which is sunk into the PFC substratum. Aqueous growth media is then added to the well, and anchorage-dependent cells added and allowed to grow.